Which countries have Mounjaro (tirzepatide) patent protection?
Mounjaro is a brand name for tirzepatide. Patent coverage is country-specific because patents are filed and granted by national patent offices (or via regional systems) rather than worldwide by default. That means tirzepatide patent status varies across jurisdictions, based on where Eli Lilly filed and what was granted.
How can you check Mounjaro patent status by country?
To see which countries have active (or still-protected) patents for Mounjaro/tirzepatide, search at the local level using either the brand name (Mounjaro) or the generic drug (tirzepatide) and relevant assignee/owner (Eli Lilly). Typical places include:
- The national patent database for each country (for example, the USPTO for the United States, the UK IPO for the United Kingdom, the EPO for many European countries).
- Patent family databases that show where a specific invention was filed (useful for mapping “which countries” from a single starting patent).
What do people usually mean by “patent in countries” (patent vs exclusivity)?
When users ask about “patent in countries,” they may be asking about either:
- Patents (legal rights granted through patent offices), or
- Regulatory exclusivity (market-authorization protections such as data exclusivity and marketing exclusivity), which can last beyond the patent term even if patents expire, or can be shorter/overlap depending on the country’s rules.
Both can affect when competitors like biosimilars (if applicable) or generics can enter, but the timing is not determined by patents alone.
Why the answer can’t be a single definitive list of countries
Without a specific patent number or a defined time point, there isn’t a reliable single-country list that applies to “Mounjaro patent in countries,” because:
- Different patent families exist (composition of matter vs. formulation vs. method-of-use).
- Different countries may have different grant outcomes (granted vs. rejected), different claim scopes, and different renewal schedules.
- Linkage to exclusivity can differ by jurisdiction.
If you tell me one thing, I can narrow it to the countries you care about
If you share either (a) the countries/regions you care about (e.g., US, UK, EU, Canada, India, China, Australia), or (b) a specific tirzepatide patent number (or a patent link), I can map the patent coverage more precisely for those jurisdictions.
Sources
No source links were provided with your question, so I can’t cite specific countries or patent documents from the information available.